|241.65 -0.42 (-0.17%)||12-08 16:00|
|Targets||6-month :||285.47||1-year :||333.42|
|Resists||First :||244.41||Second :||285.47|
|Supports||First :||228.78||Second :||219.11|
|MAs||MA(5) :||240.78||MA(20) :||233.03|
|MA(100) :||230.39||MA(250) :||234.56|
|MACD||MACD :||3.8||Signal :||2.8|
|%K %D||K(14,3) :||84.8||D(3) :||83|
|52-week||High :||281.39||Low :||204.44|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ UTHR ] has closed below upper band by 19.0%. Bollinger Bands are 21.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||244.98 - 246.19||246.19 - 247.16|
|Low:||236.74 - 238.39||238.39 - 239.73|
|Close:||239.35 - 241.84||241.84 - 243.86|
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||47 (M)|
|Shares Float||43 (M)|
|Held by Insiders||1.7 (%)|
|Held by Institutions||99.9 (%)|
|Shares Short||1,130 (K)|
|Shares Short P.Month||1,030 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||121.58|
|Profit Margin||40.8 %|
|Operating Margin||53.6 %|
|Return on Assets (ttm)||10.8 %|
|Return on Equity (ttm)||17.5 %|
|Qtrly Rev. Growth||18.1 %|
|Gross Profit (p.s.)||37.88|
|Sales Per Share||46.81|
|Qtrly Earnings Growth||9.6 %|
|Operating Cash Flow||956 (M)|
|Levered Free Cash Flow||593 (M)|
|Price to Book value||1.98|
|Price to Sales||5.16|
|Price to Cash Flow||11.88|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|